Wednesday, 18 October 2017
Meeting category
Date(s)
18 Oct 2017
Location
Toronto,
Canada
Organizer
International Workshop on HBV Cure 2017
Related Enduring Materials
Enduring Materials
Session 1: Clinical Update on HBV Cure -
Harry Janssen, MD, PhD
TAF – The latest update, which questions remain to be answered?
Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement
Is immunomodulation really needed to cure HBV?
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Session 2: New biomarkers: how will they help us? -
How to use new virological biomarkers to assess HBV cure: quantitative HBsAg, HBcrAg, HBV-RNA (not yet available)
Florian Bömmel, MD
University of Leipzig, Leipzig, Germany
To look inside or outside of the liver for evidence of HBV cure? (not available)
Georg Lauer, MD, PhD
Massachusetts General Hospital Boston, MA, USA
Session 3: Latest update on New Treatment modalities - Immunologic response -
How does HBV interact with the immune system
Innate Immunity : TLR, RIG-I, STING and potential others
Adaptive Immunity: Therapeutic vaccination, checkpoint inhibition and potential others
Session 4: Latest update on New Treatment modalities - Virologic update -
Entry inhibition
Capsid inhibition
Angela Lam, PhD
Janssen, USA
Session 5: From the science to the clinic -
Is personalized therapy needed to achieve success?
Combination therapy how to navigate in a minefield of efficacy and toxicity?
Round table discussion: Trial design, treatment endpoints and regulatory approach
Bill Symonds, PharmD
Arbutus, Burnaby, Canada
Jeffrey Murray, MD, MPH
U.S. Food and Drug Administration, USA
Henry Lik Yuen Chan, MD
Chinese University of Hong Kong, Hong Kong
Overview
Welcome
We are pleased to look back on a very successful 4th edition of the International HBV Cure Workshop, held in Toronto, ON, Canada on Wednesday 18 October 2017.
Almost 100 delegates attended the workshop and the Organizing committee and organizers would like to thank the speakers, chairs and all participants for their contribution to this meeting! In particular we would like to thank our workshop sponsors. Without their financial contribution this workshop would not have been made possible.
The Organizing committee
Background
More than 250 million people are chronically infected with hepatitis B (HBV) around the globe. The purpose of the program is to inform the participants about the developments in the possibilities to find a cure for HBV. The meeting will be highly interactive with input from experts out of the arena of basic, translational and clinical HBV research.
The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available are providing great hopes for decreasing the burden of the disease, simplifying treatment and ultimately curing and eradicating HBV infection.
In order to optimize curative treatment for HBV, outstanding speakers from around the globe will share the newest therapeutic options for viral hepatitis and experts will discuss the path forward to cure this deadly disease, leading to liver cirrhosis and liver cancer. Questions on which end points to use in therapeutic trials and how to combine different agents targeting the virus and/or immune system will be extensively discussed.
This workshop also brings together global inter-disciplinary experts to provide a framework for how academia and industry should could collaborate to achieve the goal of curing hepatitis B.
Committees
Organizing Committee
The members of the Organizing Committee (OC) discuss, on a frequent basis, the scientific program of the workshop, identify interesting topics and candidate speakers.
Support
Sliver Level
Bronze Level
Supporter Level
Contributor
Official Media Partners
Language
Related Programs
